中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
2期
143-147
,共5页
汤传昊%刘晓晴%高红军%李俭杰%郭万峰%李晓燕%王伟霞%刘冰%曲莉莉%王维威
湯傳昊%劉曉晴%高紅軍%李儉傑%郭萬峰%李曉燕%王偉霞%劉冰%麯莉莉%王維威
탕전호%류효청%고홍군%리검걸%곽만봉%리효연%왕위하%류빙%곡리리%왕유위
厄洛替尼%非小细胞肺癌%治疗
阨洛替尼%非小細胞肺癌%治療
액락체니%비소세포폐암%치료
Erlotinib%Non-small cell lung cancer%Therapy
目的 观察厄洛替尼单药治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法 104例晚期NSCLC患者给予厄洛替尼150 mg口服治疗,每日1次,服用至疾病进展或出现不可耐受的不良反应.采用实体瘤的疗效评价标准评价疗效.采用美国国家癌症研究所毒性评价标准评价不良反应.结果 104例患者均可评价疗效,客观有效率为27.9%(29/104),疾病控制率为76.0%(79/104),中位无进展生存时间为5.1个月,中位生存时间为13.1个月,1年总生存率为61.5%.多因素生存分析显示,PS评分为0～1分、腺癌和治疗后出现皮疹的患者具有显著的生存优势(均P<0.05);而吸烟和肝转移则显著增加了死亡风险(均P<0.05).厄洛替尼治疗晚期NSCLC最常见的不良反应是皮疹和腹泻,发生率分别为73.1%和41.3%.不良反应多为1～2级,3～4级不良反应的发生率仅为6.7%.结论 厄洛替尼治疗晚期NSCLC的疗效确切,患者耐受性良好,可作为化疗失败、不适合或拒绝接受化疗的晚期NSCLC患者的治疗选择.
目的 觀察阨洛替尼單藥治療晚期非小細胞肺癌(NSCLC)的療效和不良反應.方法 104例晚期NSCLC患者給予阨洛替尼150 mg口服治療,每日1次,服用至疾病進展或齣現不可耐受的不良反應.採用實體瘤的療效評價標準評價療效.採用美國國傢癌癥研究所毒性評價標準評價不良反應.結果 104例患者均可評價療效,客觀有效率為27.9%(29/104),疾病控製率為76.0%(79/104),中位無進展生存時間為5.1箇月,中位生存時間為13.1箇月,1年總生存率為61.5%.多因素生存分析顯示,PS評分為0～1分、腺癌和治療後齣現皮疹的患者具有顯著的生存優勢(均P<0.05);而吸煙和肝轉移則顯著增加瞭死亡風險(均P<0.05).阨洛替尼治療晚期NSCLC最常見的不良反應是皮疹和腹瀉,髮生率分彆為73.1%和41.3%.不良反應多為1～2級,3～4級不良反應的髮生率僅為6.7%.結論 阨洛替尼治療晚期NSCLC的療效確切,患者耐受性良好,可作為化療失敗、不適閤或拒絕接受化療的晚期NSCLC患者的治療選擇.
목적 관찰액락체니단약치료만기비소세포폐암(NSCLC)적료효화불량반응.방법 104례만기NSCLC환자급여액락체니150 mg구복치료,매일1차,복용지질병진전혹출현불가내수적불량반응.채용실체류적료효평개표준평개료효.채용미국국가암증연구소독성평개표준평개불량반응.결과 104례환자균가평개료효,객관유효솔위27.9%(29/104),질병공제솔위76.0%(79/104),중위무진전생존시간위5.1개월,중위생존시간위13.1개월,1년총생존솔위61.5%.다인소생존분석현시,PS평분위0～1분、선암화치료후출현피진적환자구유현저적생존우세(균P<0.05);이흡연화간전이칙현저증가료사망풍험(균P<0.05).액락체니치료만기NSCLC최상견적불량반응시피진화복사,발생솔분별위73.1%화41.3%.불량반응다위1～2급,3～4급불량반응적발생솔부위6.7%.결론 액락체니치료만기NSCLC적료효학절,환자내수성량호,가작위화료실패、불괄합혹거절접수화료적만기NSCLC환자적치료선택.
Objective Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a significant improvement of survival in non-small-cell lung cancer (NSCLC) after the failure of front-line chemotherapy. The aim of this study was to evaluate the antitumor efficacy and toxicity of Erlotinib in the treatment of advanced NSCLC patients. Methods A total of 104 patients with advanced NSCLC admitted in our department during December 2006 to November 2008 were enrolled in this study. Eligible patients received oral Erlotinib 150 mg/d until disease progression or intolerable toxicity. Best clinical response was determined using RECIST criteria, the adverse events were evaluated according to the NCI criteria. Results The total effective rate was 27.9% (29/104) and the clinical benefit was 76.0% (79/104). The median progression-free survival was 5.1 months (95% CI 4.0-8.0). The median survival time was 13.1 months (95% CI 10.0-15.7 ). The 1-year survival rate was 61.5%. Significant survival benefit from erlobinib therapy was observed for patients with good personal status (HR 0.56, P=0.006), adenocarcinoma (HR 0.43, P= 0.004) and skin rash (HR 0.46, P=0.005). But patients with smoking ( HR 2.75, P < 0.001) and liver metastasis (HR 2.91, P=0.002) add the risk of death. The adverse events were mild (grade≤2), most common toxicities were skin rash in 73.1% (76/104) and diarrhea in 41.3% (43/104). Only 6.7% (7/104) patients got adverse events of grade ≥ 3. Conclusion Erlotinib is an effective and well-tolerated treatment option for advanced NSCLC and could offer an alternative for patients after the failure of first-line chemotherapy, unsuitable for or not wishing to receive chemotherapy.
